Abstract:Alport syndrome (AS) is a hereditary kidney disease associated with proteinuria, hematuria and progressive kidney failure. It is characterized by a defective glomerular basement membrane caused by mutations in type IV collagen genes COL4A3/A4/A5 which result in defective type IV collagen α3, α4, or α5 chains, respectively. Alport syndrome has three different patterns of inheritance: X-linked, autosomal and digenic. In a study of CKD of unknown etiology type IV collagen gene mutations accounted for the majority of the cases of hereditary glomerulopathies which suggests that AS is often underrecognized. The natural history and prognosis in patients with AS is variable and is determined by genetics and environmental factors. At present, no preventive or curative therapies exist for AS. Current treatment includes the use of renin-angiotensin-aldosterone system inhibitors which slow progression of kidney disease and prolong life expectancy. Ramipril was found in retrospective studies to delay the onset of ESKD and was recently demonstrated to be safe and effective in children and adolescents, supporting that early initiation of Renin Angiotensin Aldosterone System (RAAS) blockade is very important. Mineralocorticoid receptor blockers might be favorable for patients who develop "aldosterone breakthrough." While the DAPA-CKD trial suggests a beneficial effect of SGLT2 inhibitors in CKD of non-metabolic origin, only a handful of patients had Alport in this cohort, and therefore conclusions can't be extrapolated for the treatment of AS with SGLT2 inhibitors. Advances in our understanding on the pathogenesis of Alport syndrome has culminated in the development of innovative therapeutic approaches that are currently under investigation. We will provide a brief overview of novel therapeutic targets to prevent progression of kidney disease in AS. Our review will include bardoxolone methyl, an oral NRf2 activator; lademirsen, an anti-miRNA-21 molecule; sparsentan, dual endothelin type A receptor (ETAR) and angiotensin 1 receptor inhibitor; atrasentan, oral selective ETAR inhibitor; lipid-modifying agents, including cholesterol efflux transporter ATP-binding cassette A1 (ABCA1) inducers, discoidin domain receptor 1 (DDR1) inhibitors and osteopontin blocking agents; the antimalarial drug hydroxychloroquine; the antiglycemic drug metformin and the active vitamin D analog paricalcitol. Future genomic therapeutic strategies such as chaperone therapy, genome editing and stem cell therapy will also be discussed.

Clinical practice recommendations for the treatment of Alport syndrome: a statement of the Alport Syndrome Research Collaborative

Expert guidelines for the management of Alport syndrome and thin basement membrane nephropathy.

[Expert consensus on the diagnosis and treatment of Alport syndrome (version 2023)]

Novel Therapies for Alport Syndrome

Advances and Unmet Needs in Genetic, Basic and Clinical Science in Alport Syndrome: Report from the 2015 International Workshop on Alport Syndrome.

Long-term treatment by ACE inhibitors and angiotensin receptor blockers in children with Alport syndrome

Alport Syndrome: Clinical Utility of Early Genetic Diagnosis in Children

Exploration of Gene Therapy for Alport Syndrome

Expert Consensus Guidelines for the Genetic Diagnosis of Alport Syndrome

Alport syndrome: Expanding diagnosis and treatment

Renal, Auricular, and Ocular Outcomes of Alport Syndrome and Their Current Management

Alport Syndrome: a Unified Classification of Genetic Disorders of Collagen IV Alpha 345: a Position Paper of the Alport Syndrome Classification Working Group

Pharmacological approach and diagnosis for Alport syndrome

A comprehensive review of Alport syndrome: definition, pathophysiology, clinical manifestations, and diagnostic considerations

Outcome of Renal Transplantation in Patients with Alport Syndrome: Report of 11 Cases

IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome

[Clinical and Pathological Study of 47 Cases with Alport Syndrome].

Stem Cell Therapy for Alport Syndrome: the Hope Beyond the Hype

IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome

[Analysis of Diagnosis and Treatment of Alport Syndrome].

Genotype–phenotype correlations and nephroprotective effects of RAAS inhibition in patients with autosomal recessive Alport syndrome